Novel isoxazolopyridone derivatives that are metabotropic glutamate receptor (mGluR) 7 antagonists were discovered and pharmacologically characterized. 5-Methyl-3,6-diphenylisoxazolo [4,5-c]pyridin-4(5H)-one (MDIP) was identified by random screening, and 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazolo [4,5-c] In CHO cells coexpressing human mGluR7 with G␣ 15 , MDIP and MMPIP also inhibited the L-AP4-induced cAMP response. The maximal degree of inhibition by MMPIP was higher than that by MDIP in a cAMP assay. MMPIP was able to antagonize an allosteric agonist, the N,NЈ-dibenzhydryl-ethane-1,2-diamine dihydrochloride (AMN082)-induced inhibition of cAMP accumulation. In the absence of these agonists, MMPIP caused a further increase in forskolin-stimulated cAMP levels in CHO cells expressing mGluR7, whereas a competitive antagonist, LY341495, did not. This result indicates that MMPIP has an inverse agonistic activity. The intrinsic activity of MMPIP was pertussis toxin-sensitive and mGluR7-dependent. MMPIP at concentrations of at least 1 M had no significant effect on mGluR1, mGluR2, mGluR3, mGluR4, mGluR5, and mGluR8. MMPIP is the first allosteric mGluR7-selective antagonist that could potentially be useful as a pharmacological tool for elucidating the roles of mGluR7 on central nervous system functions.Metabotropic glutamate receptors (mGluRs) belong to a family of G protein-coupled receptors thought to contribute to the modulation of neuronal excitability and neurotransmitter release. Eight mGluR subtypes (mGluR1-mGluR8) have been cloned, and they have been classified into three groups based on sequence homology, pharmacological profile, and signal transduction pathway. mGluR1 and mGluR5 belong to group I mGluRs, and they are coupled to phospholipase C and subsequent intracellular calcium release via G q protein. mGluR2 and mGluR3 belong to group II mGluRs, whereas mGluR4, mGluR6, mGluR7, and mGluR8 belong to group III mGluRs. The subtypes of group II and group III mGluRs are negatively coupled to adenylate cyclase via G i protein (Conn and Pin, 1997 , 5-methyl-3,6-diphenylisoxazolo[4,5-c

No abstract

No abstract

over CDK1, 2, 5, 7, and 9. -Screening and medicinal chemistry techniques, supported by molecular modeling, identifies compound (I) containing the novel pyrimidinylaminothiazole scaffold as a potent CDK4 inhibitor. Introduction of a methyl group at the C-5 or C-6 position on the pyrimidine ring directed toward the gate keeper residue of CDK4 (Phe93), greatly enhances the CDK4 selectivity over other CDK family kinases. (I) shows sufficient aqueous solubility and potently inhibits pRb phosphorylation and BrdU incorporation in tumor models. -(SHIMAMURA, T.; SHIBATA, J.; KURIHARA, H.; MITA, T.; OTSUKI, S.; SAGARA, T.; HIRAI, H.; IWASAWA*, Y.; Bioorg.

No abstract